sign in sign up
<<
Home , Neuropsychopharmacology

ecnp matters NEWSLETTER NO. 9, Oct. 2005

macology has slowly regained its prominence Neuropsychopharmacology in in The Netherlands. The pharmacological Page 1/5 departments moved to basic Interview with Hans-Ulrich Wittchen The Netherlands research, particularly in Amsterdam and on Size and Burden of Mental Utrecht, and have been linked nowadays to Disorders in Europe René S. Kahn, local advisor of the 18th ECNP Congress, University Medical Centre Utrecht clinical research, concentrating more and more on translation research. Page 2/3/4 Neuropsychopharmacology has a long but eventful past in The Netherlands. The Reports on ECNP activities research in this field was initiated and embedded in the two major pharmacological In Amsterdam (Free University) the empha- research trends in the Netherlands, starting with the appointment of the German physi- sis is on Alzheimer’s disease and some neuro- ologist and pharmacologist Rudolf Magnus (1908) and the German endocrinologist logical disorders. In Utrecht (Rudolf Magnus Page 3 Ernst Lacquer (1920) in Utrecht and Amsterdam, respectively. Institute of Neuroscience) psychiatric disor- Call for nominations ders, like schizophrenia and autism, are Basic history studies were initiated by Herman M. van investigated. The studies on both locations An important contribution to psychophar- Praag, at Groningen University. His studies make use of modern imaging techniques and macology from the Magnus line was the focused on the role of serotonin in depres- more recently of genomics methodology. behavioural research by Jacques M. Van sion and were of major impact in establish- Rossum, performed in Nijmegen’s labora- ing, through CSF studies, the role of sero- Large, combined clinical studies are now tory of the famous inventor of the molecular tonergic mechanisms in major depression. being conducted in all university psychi- theory, Everhardus J. Ariëns. The Whether it was through his studies or not, was going on and also protested against atric centers in which psychopharmaco- behavioural studies of Van Rossum signifi- the pharmaceutical company Solvay was one ECT that was considered a cruel treatment. logical research is being supplemented by cantly contributed to the hypoth- of the first to develop a selective serotonin Unfortunately, it was research at Utrecht genetic and neuroimaging investigations. esis of schizophrenia. Interestingly, the co- receptor inhibitor, fluvoxamine, which is still University that served as focus point for this Funding has been obtained from the Dutch operation of Lacquer with a large meat widely used as an . group. Its gripes were not based on scientific Government to continue cohort studies in cannery in Oss resulted in the founding of data nor were these limited to scientific the field of anxiety and depression, schizo- the pharmaceutical company Organon. Subsequently studies were initiated in debate but instead degenerated into person- phrenia, childhood disorders and addiction. Utrecht on the role of serotonin in anxiety alized attacks on the researchers themselves. These studies, including more than 1,000 In the tradition of the Lacquer line, the endo- disorders by one of his students, René Kahn, This movement did in patients each, offer the hope of scientific crinologist David De Wied started a large currently holding the Chair of the Netherlands a great disservice. breakthroughs in the field of environmental INTRODUCTION research programme on neuropeptides and in Utrecht that Van Praag held during As a consequence of the above, in the last two and genetic influences on the origin of these european college of Important addresses brain function after his appointment (1963) that time. While in Utrecht, Van Praag, decades of the twentieth century basic as well disorders as well as information (pharmaco- neuropsychopharmacology

organising secretariat: 18th ecnp congress as professor of in Utrecht and in collaboration with the Rudolf Magnus as clinical psychopharmacological research in ) on why some patients benefit and CONGREX HOLLAND BV PO Box 302 renamed the pharmacological laboratory in Institute, performed clinical trials on g-type the Netherlands saw a pronounced decline. others do not fromfuture psychopharmacologicalevents For all your questions 1000 AH Amsterdam regarding: The Netherlands • Abstracts phone: +31 20 504 0207 Rudolf Magnus Institute. Studies were per- endorphins and schizophrenia, engendering Some groups in Amsterdam and Nijmegen treatment. Particularly,ecnp congresses: the interrelationship • Hotels fax: +31 20 504 0225 19th ECNP Congress, Paris - France • Logistics e-mail: [email protected] formed on fragments in animals, humans quite some excitement. Eventually, however, remained active however. Indeed, the studies with basic neuroscienceSeptember 16 - 20, 2006 will stimulate the • Registration e-mail: [email protected] th 20 ECNP Congress, Vienna - Austria • Exhibition (for questions regarding October 13 - 17, 2007 registration & hotels only) and patients, resulting in hypotheses con- it proved not to be a viable intervention in at the Rudolf Magnus Institute kept the rep- finding of new drug21st ECNP targets.Congress, Barcelona Indeed,- Spain the cur- website: www.congrex.nl August 30 - September 03, 2008 cerning ACTH neuropeptides and attention the treatment for schizophrenia. This holds utation in the Netherlands from going belly- rent century starts22nd ECNP withCongress, psychiatricIstanbul, Turkey and psy- Express mail and courier service: th September 12 - 16, 2009 18 18 ecnp congress For further information: CONGREX HOLLAND BV and motivation processes, vasopressin- and also for all neuropeptides tested in patients up. Although studies on the mechanism and chopharmacologicalOrganising researchsecretariat: having Scientific secretariat: attained th A.J. Ernststraat 595 k 19th ECNP Congress ECNP-Office ECNP 1082 LD Amsterdam Congrex Holland BV P.O. Box 85410 The Netherlands oxytocin neuropeptides and memory proc- so far. role of in depression were continued by a prominent placeP.O. Box 302 in The3508 Netherlands.AK Utrecht 1000 AH Amsterdam The Netherlands scientific secretariat: 18th ecnp congress th ecnp-office esses, and endorphin neuropeptides and Rudy H. van den Hoofdakker in Groningen Multiple researchThe Netherlands groups are activephone: +31 30and253 8567 pro- Congress 18 ECNP Congress phone: + 31 20 50 40 200 fax: +31 30 253 8568 PO Box 85410 fax: + 31 20 50 40 225 e-mail: [email protected] October 22 - 26, 2005 3508 AK Utrecht schizophrenia. The current director of the Discordance and some studies on serotonergic mecha- ductive so that neuropsychopharmacologicale-mail: [email protected] website: www.ecnp.nl Amsterdam, The Netherlands The Netherlands phone: +31 30 253 8567 Rudolf Magnus Institute of Neuroscience, The darker side of psychopharmacologi- nisms in anxiety disorders by Herman G.M. research in The NetherlandsWorkshop on neuropsychopharmacology can currently for young be fax: +31 30 253 8568 scientists in europe: e-mail: [email protected] website: www.ecnp.nl March 9 - 12, 2006 2005 Jan M. Van Ree, contributed to these stud- cal research in The Netherlands occurred Westenberg in Utrecht, not much else was held to the highestNice – Franceinternational standards. congress venue: Amsterdam International Fairs Topics: & Congress Centre (RAI) ies and also investigated the significance of around the same time i.e. the late seventies, done in the field of psychopharmacology in Molecular Neuropsychopharmacology Europaplein 14 Behavioural Pharmacology 1078 GZ Amsterdam Clinical Neuropsychopharmacology The Netherlands endorphins for addiction. early eighties of the twentieth century. The clinical settings during those years. Anxiety: towards new targets phone: +31 20 549 1212 fax: +31 20 646 4469 anti-psychiatry movement was rather strong ecnp consensus meeting: website: www.rai.nl March 12 - 15, 2006 Clinical history in our country. It lambasted the (relatively High standard Nice - France Topic: Psychiatric disorders in older people For information on Nice meetings: In the psychiatric realm pharmacological little) psychopharmacological research that Since the mid nineteen nineties psychophar- ECNP-Office

P.O. Box 85410 www.ecnp.nl 3508 AK Utrecht The Netherlands phone: +31 30 253 8567 fax: +31 30 253 8568 e-mail: [email protected] website: www.ecnp.nl New at the 18th ECNP Congress The Size and Burden of Mental in Amsterdam: a Breaking News Disorders in Europe session Interview with Hans-Ulrich Wittchen, principal investigator David J. Nutt, chair Scientific Programme Committee of the ECNP Task Force

The Scientific Programme Committee is proud to present a Breaking News session right Maria Vrijmoed – de Vries, editor before the official start of the 18th ECNP Congress in Amsterdam Hans-Ulrich Wittchen, Professor of Clinical and Epidemiology at the When Technical University Dresden, Germany will be giving a plenary lecture on Tuesday The session is scheduled for Saturday October 25 at the 18th ECNP Congress in Amsterdam, The Netherlands. In his lecture October 22, 2005 from 18.00 to 19.15 he will discuss the outcome of an unprecedented comprehensive EU-wide Task Force hours and will take place in the FORUM study on “The size and the burden of mental disorders in Europe”, commissioned by room, RAI Congress Centre. ECNP.

What Why is such a study needed? a coordinated EU-wide study program that European scientists were asked to encourage informs us about such core questions like submitting abstracts describing new findings In the past decade, it has become increas- “How many adults in the EU suffer each in relation to the current status of neu- ingly evident that it is impossible to make year from major depression, panic disorder, ropsychopharmacology and/or neuroscience sound statements about the prevalence and and other substance abuse disorders research. Five proposals, preferably showing burden of mental disorders, or more gener- or dementia?”, “Are prevalence rates on the a mix of preclinical and clinical research, will ally speaking, disorders of the brain. Despite increase?”, or “How many of those affected be selected by the SPC to be presented at a rich European tradition in epidemiological are treated?” The lack of such a coordinated the Breaking News session. Each lecture will research in many countries and regions, sound data base for the EU has led to the consist of an oral presentation of 10 minutes, the heterogeneity of designs and methods unfortunate situation that prevalence find- followed by a discussion of 5 minutes. on the one side and the diversity of health ings from single epidemiological studies with care systems on the other made it quite dif- a particular research interest and according Details ficult to provide a coherent picture of the methodological adjustments are frequently The detailed programme of the Breaking frequency of mental disorders and conse- uncritically generalized. The resulting vari- News session will be available on-line quently the facets of burden associated with ation in findings causes confusion not only (www.ecnp.nl) by October 10, 2005. them. Unlike the US, Canada and Australia with long traditions of regular standardized mental health surveys, there has never been continued on page 5

1 Moscow 2005: th Intense interest Poster Award Winners 8 ECNP Regional Meeting Moscow Both European and Russian scientists had much to demonstrate. For instance, stud- Clinical research: Sergey Seredenin, chair Local Organising Committee ies on psycho-emotional stress treatment P.6.041 Dopamine D2 receptor which are conducted in the State Zakusov gene and drug abuse: prevalence 800 Neuropsychopharmacologists gathered in Moscow from April 14 to 16 in the build- Institute of Pharmacology (RAMS) headed of combined A1/A2 Taq1 A and ing of the Moscow Government to participate in the 8th ECNP Regional Meeting. by Professor S. Seredenin have generated an C/C NcoI genotypes in alcohol intense interest. and heroin-dependent patients Founder of neuropsychopharmacology Professor Sergey Seredenin, President of The attractive programme of keynote lec- Inna Shamakina, Russia It is very meaningful that this event occurred the Russian Local Organizing Committee, tures and satellite symposia covered the in Russia, Dmitry Kharkevich, President of believes that nowadays science can not exist aspects of correctional pharmacotherapy of Preclinical research: Russian Scientific Society of Pharmacology and rapidly advance within a rigid frame- depression, anxiety and fear, aging, alcohol- P.4.001 Use of DNA/ said, since it was the Russian scientist Ivan work defined by boundaries within a certain ism, tobacco smoking and narcomania. Array for profiling Pavlov, who laid down the foundation of neu- field. In this light, the main ECNP force factors activated by aminoada- ropsychopharmacology. There is no present is to act as a multidisciplinary centre of Winners mantane compound Ladasten in without the past, and the methods that Ivan state-of-art knowledge in various fields of The poster sessions were also very informa- rat brain Pavlov developed alone, provide a solid basis science. tive. A special opportunity was realized for Julia Vakhitova, Russia for current studies on the . young Russian scientists. Among the partici- Strong impetus pants of the meeting 5 Travel Award winners Therefore, every ECNP congress and meet- and 2 Poster Award winners were chosen. Travel Award Winners ing gives a strong impetus to the advance- ment of neuropsychopharmacology. Valuable contribution P.2.016 Influence of atypical Unfortunately, not all Russian scientists are According to the opinion of the leading neuroleptic on cells in able to take part in the international sci- Russian scientists the meeting provided a patients with shizophrenia in the entific events. Organizing the 8th ECNP valuable contribution to the development course of the therapy Regional Meeting in Russia provided repre- of medical science. It allowed the research- Ivanova Svetlana, Tomsk, Russia sented Russian researchers with a remarkable ers to communicate and exchange the latest P.3.005 The influence of 5HT1A occasion to stay abreast with the up-to- results and get access to updated informa- receptor ipsapirone and date developments and advances of science tion on advancements in related sciences. buspirone on anxious-depressive worldwide. Furthermore, guidelines were elaborated mice: comparison of acute and regarding novel designs and programs for chronic treatments The meeting gathered about 500 specialists treating the diseases of social concern, as well Avgustinivich Damira, in European Neuropsychopharmacology and as outlining the prospects for future interna- Novosibirsk, Russia more than 300 participants presented Russia tional collaboration. P.3.011 Genetic dependence of during the meeting. Russian specialists CCK-2 antagonists and agonists pointed out that no comparably significant Abstracts are available on www.ecnp.nl (go psychotropic effects scientific event in neuroscience was organ- to Meetings; Regional meetings) Kolik Larissa, Moscow, Russia ized in the country for over 20 years. P.3.017 Effect of afobazol on brain-derived neurotrophic fac- tor protein in brain of inbred mice exposed to emotional stress Melkumjan Diana, Moscow, course was organized, both scientifically and Follow-up/Yearly summer course Russia Educational Team Romania logistically, made me more optimistic about It seemed likely that other young psychiatrists P.3.051 Estimation of placebo my perspectives in psychiatry”. from Romania would like to participate in a effect in therapy of Generalized Mihai-Dumitru Gheorghe, local coordinator Educational Team Romania course of this kind too, because the interest Dr. Dana Sichitiu, resident at the Psychiatric in psychopharmacology and research of the Chakhava Vasily, Moscow, Russia rom April 7-9, 2005 an interactive course for young psychiatrists took place Department of the Central Military Hospital, younger Romanian generation was clearly evi- F at Poiana Brasov, a mountain resort in Romania. Two ECNP experts, profes- Bucharest, Romania: “During the 2 days of dent at the ECNP Educational Team meeting sors Joseph Zohar and Michael Davidson worked with 42 young psychiatrists from discussions, analyses and talks, I obtained in Poiana Brasov. The Romanian Association Romania 2005: Award Romania. two important things: confidence in myself for Psychopharmacology has decided to organ- Winners and the wish to improve myself in the future. ize a yearly summer course for young psychia- Themes emphasized the importance of early identifi- This course proved for me to be an evalua- trists from Romania. The first meeting of this Treatment particularities in first In Romania there is great interest in, and a cation of risk cases even from the prodromal tive assessment of my knowledge level and kind took place on July 12-15, 2005. The episode of schizophrenia national program about, first episode schizo- period. The aspect of early identification in the discussions I had with professors Zohar theme was: Basics in psychopharmacology. Valentin Matei phrenia and depression. Also, during recent the interventions and studies in schizophre- and Davidson were very useful. I would like Cortical areas connectivity and years, depression has shown an increased nia was also discussed by a number of the to thank professor Gheorghe for giving me Thank you, ECNP auditory hallucinations incidence especially in the young socio–pro- participants. the opportunity to participate in such an In conclusion, in my role as local coordi- Corneliu Mosoiu fessional active population of Romania. The Professor Zohar considered early clinical activity. I hope that ECNP will organize nator of the Educational Team Romania, meeting provided the opportunity to elabo- diagnosis and therapeutical intervention to other courses in Romania in the future as I would like to say, not only on behalf of Diagnostic and therapeutic gaps rate on the point of view of early clinical obtain remission and clinical recovery in well in order to help the development of myself but also on behalf of the participants: in anxious-depressive state diagnosis as well as the psychopharmacologi- depression. In addition, the importance of psychiatric research and psychopharmacol- “thank you, ECNP, for your support and for Simona Tamasan cal intervention modalities in both schizo- research on the early identification of risk ogy, because young psychiatrists in Romania the fact that the young psychiatrists from phrenia and depression. factors for therapeutical resistance develop- truly need this”. Romania were given this opportunity”. ment was presented. We hope that ECNP will organise similar EUROPEAN COLLEGE OF At the start of the meeting the level of inter- Dr. Davidson and Dr. Zohar, as well as Dr. Melitina Nedelcu, psychiatrist at the activities in Romania in the future. I would NEUROPSYCHOPHARMACOLOGY est of the young generation of psychiatrists myself, promoted the idea of a medical Psychiatric Department of the Obregia also like to take this opportunity to thank for the research aspects in psychiatry, their approach model to any kind of psychiatric Hospital, Bucharest, Romania: “For me, Iris Allebrandi from the ECNP - Office and neurobiological basis and their knowledge disorder. this course was a unique experience, because my colleague Dr. Alexandru Grigoriu, for level of such a difficult field as psychophar- of the direct and open style of communica- the excellent (local) organization. macology was established. Based on this, the Direct communication tion. This course offered me useful skills present day medical thinking was addressed The participants especially appreciated the which will help me in my work as a psy- Abstracts are available on www.ecnp.nl (go with the aim of giving a comprehensive over- quality of the discussions and the oppor- chiatrist”. to Meetings; Educational meetings) view on the modern clinical and therapeutic tunity for direct communication with the approach, in particular with the desire to experts. The presentation of the latest data develop and increase the level of perform- from the research on schizophrenia and ance in Romania. depression was also considered very valu- able. Answers could not always be found There were a lot of questions and analyses; Participant´s opinions suggestions were made and experiences of Dr. Gabriela Hendoreanu, resident at the 19 th ECNP Congress clinical and therapeutical situations in psy- Psychiatric Department of the Obregia September 16 - 20, 2006 Paris, France chiatric practice discussed. As always, not Hospital, Bucharest, Romania: ”I was all the answers to the questions could be extremely happy to participate in such an found. event and I was impressed that professors Professor Davidson presented an overview Zohar and Davidson listened to us carefully of schizophrenia across the lifespan and he and answered all our questions. The way this

2 Maria Gabriella Scordo, SwedenScordo,Gabriella Maria associations. six these of the journals official the of boards editorial on is He (CINP). Neuropsychopharmacology of Colleges International and American Canadian, the of fellow a as Neuropsychopharmacology,well of as College European the of Psychopharmacologyand for Association British Psychiatry,the Biological of for Society the of member a is He papers. 200 over with author published well a is and field, his in lectures international and national 250 over delivered has psychopharmacology.Dr.Blier in butions contri outstanding for Neuropsychopharmacology of College in International Awardthe from Hamilton 1998 Max the particular in research, groundbreaking his for awards several received has Blier Dr scientist, world-renowned a As PsychopharmacologyGovernment. Federal Canadian in the by Chair Research Canada prestigious the awarded been also has He Mood in Chair Endowed the of recipient Disorders Research at the the University of and Ottawa, Institute of Mental Ottawa Health Research of (IMHR). University the at Dr. Pierre Blier is a full professor in the departments of Psychiatry and Cellular and Molecular www.ecnp.nlcheck details. Please for WorkshopECNP Neuropsychopharmacology- Youngfor on Europe in Scientists Congresses ECNP at fee registration waived or Reduced - Awards- scientists: young for incentives following the installed has ECNP scientists Europeanyoungfor incentives ECNP n mliicpiay prahs r also institu our at missing is still ongoing. What are approaches multidisciplinary complementary and of and use the in Investigations schizophrenia. and psychiatry forensic psychiatry, youth disorders, on anxiety focusing units research are there Unit, Moodthe Disorders to Researchaddition In the at up built research Research?HealthMental of Institute the is How participant’s point of view of participant’spoint The a from Workshop2005 Nice Disorders Mood the in focus research The health mental of area the in Ottawa University the at collaborations more cre ate will this hope I and expert “imaging” estab an recruiting of process the in are programme.We imaging full-fledge a is tion Pharmacology. I Maria Vrijmoedde Vries,– editor France.Nice, 2005 3-6, March Europe in scientists foryoung Neuropsychopharmacology on ECNP Workshop the at Blier Pierre with Interview and used in dementia, in pharmacological effects of , variability and inter-individual the to receptors transporters , drug metabolising for coding of genes contribution in polymorphisms the on is researches doc Clinical post- my in of focus PhDmain the Pharmacology, the getting After lems. psychoactive prob with related health and dealing side-effects drugs been , in have specialist I as and MD, As outcome. long-term and compliance otherwise and increaseefficient drugs, the risk of non- of use the limit often reactions drug adverse various response, insufficient or of lack from Apart patients. of portion compounds, far from optimal in a large pro new many of introduction the despite still, is dementia and schizophrenia depression, includ disorders mental of treatment Drug donepezil with therapy in Disease Alzheimer’s with patients in morphism poly- CYP2D6 of impact P.313 : bridging animal and human studies” at the session on Behavioural on “Neuropsycho- session theme the at the studies” human address and to animal bridging invited pharmacology: was PhD MD, Blier, Pierre Nice, n

interview research. lished ing of - - - - group of patients. of group problematic this treat successfully to ability our increase to hope our I programme, research of help the With plans. treatment cal psychopharmacologi further for physician their by referred individuals ment-resistant treat and investi projects our research gator-initiated in participating These patients basis. daily are a on patients see still I back! and clinic the to findings research basic and translating in collaborations, multidisciplinary and interdisciplinary in opportunities great bles are projects carried out at the same institution. This ena clinical and laboratory the in research fundamental Both spectrum. its entire in disorders mood on is Unit Research pharmacology has given me the chance the me given has chopharmacology o pae y nweg i m fed of future field my improve to my and interest in knowledge my update to Attending the ECNP workshop on optimal. be to likely not is that treatment avoid to therapy their alter prospectively to then and , unacceptable develop to disposed either not to respond to therapy or pre genetically patients identify to order in www.ecnp.nlWorkshops)to (go at available are posters and Abstracts lecture. each followed that discussions ing stimulat the also appreciate truly I mation. infor acquirescientific to useful chance ing appeal extremely an represented scientists, young by given communications short and of lectures given by key speakers in the field, combination excellent The collaborations. future build help hopefully that tionships in the same field, therefore establishing rela working scientists with discuss and meet to chance the had I sessions, poster rich very sed and organised well the during Besides, plans. Neuropsy­ research ------

Call for Nominees for Call h cmons ee o oiial mar originally not were compounds the • compounds. marketed tiated studies with new compounds as well as • of compounds marketed combinations marketed different of or doses medications higher for with non-responders, are example who patients in • studies: clinical of types differentthree distinguish may One better,faster.get and patients more make to is goal studies. ultimate animal The new initiate may that observations clinical from derived be even approach, may hypotheses an new such From aspects. both in especially research, involved directly is person one least at when translational true of model ideal an is environment. This clinical a in laboratory the in generated pharmacophysiology hypothesis and macochemistry phar a investigate to is studies” human and The philosophy behind the “bridging animal humans? in experiments animal “repeat” really and you Do intriguing. rather animal is studies’ human bridging pharmacology: ‘Neuropsycho- lecture your of title The MD) becoming after years five first within training research in (MD's Residents - - - is: scientist Europeanyoung for definition The How did you come to make these? make to youcome Howdid ani high-tech nice, very with phy In your lecture, you illustrated your work. animal on based keted, (Workshop: within first four years of employment after having received their PhD) their received having after employment of years four (Workshop:first within PhD) their received having after university or institute scientific a at employment of years four first within (Congresses: Postdocs student PhD Award: NeuropsychopharmacologyECNP The objective of this award is to rec macology and related disciplines. related and pharmacology neuropsycho­ in research outstanding tde o ohr niain fr which for indications other on Studies investigator-ini but Industry-sponsored, compounds marketed with studies Open

mations. phi ognize loso­ - - -

year on a different topic. different a on year participate in this annual event focused each to peers their encourage to attendees the by I hope certainly that the I really enjoyed participating in the workshop. weregains the and present persons senior more of group the by intimidated not were They interact. to opportunity this of advan took really who youngsters bright clearly were individuals junior The tions. interac high-level for opportunity excellent an provides clinicians and of scientists group junior a and investigators senior few a together Bringing idea. terrific a is Europe nuso i te eia fed Wt my With field. medical the in incursion their further expand UniversityFloridato of the at was I when me contacted They cer. can breast of detection the for Radiology in was application medical first Their use. military for programs recognition airplane and simulations flight 3D com made a that by pany use in was technology basic The h wrso hl fr on sinit in scientists young for held workshop The the Workshop? of concept the about think you do What library.self-standing complete a in quently subse and projects individual the sponsored that DVD industries pharmaceutical on the through available become progressively will animations These understand. to easy issues complex makes and tool learning ing disorders.It really provides appeal visually a psychiatric various in action exert beneficial their may approaches new how and work medications existing how on animations 3D create to able were we sponsors, of help the and concepts graphic illustrations, of bank tions to neuropsychopharmacology.to tions contribu outstanding lifelong ognize rec to is award this of objective The AchievementLifetime Award:ECNP word will go around recipro ecnp - - tage cal. - - - - - psychopharmacology Michel Le Moal,France Le Michel Award2005 Neuro ECNP Winner 3 matters

­ interview New set-up of the Educational Report on the ECNP at ACNP Track David J. Nutt, chair Scientific Programme Committee

Joseph Zohar, chair Education Committee Just to remind you, ECNP had an inter-dis- to both anxiety disorders and alcoholism. She ciplinary research symposium at the ACNP also presented data on first sub-type selective he educational track in the ECNP meeting is aimed at providing up-to-date, bal- Annual Meeting Puerto Rico, December (alpha-5 selective) tracer for this receptor, Tanced, scientifically sound overviews of a specific topic. The goal is to provide clini- 2004. revealing an interesting distribution that was cians or scientists with updated information in an area that is not necessarily his/her very limbic centred. main focus of research in an interactive manner. Uwe Rudolph presented beautiful data on how to use knock-outs to determine the The final speaker, Giovanni Biggio, showed different roles of the multiple sub-types of the very new data on how adaptive responses to In the era of internet, when data is eas- The idea is that each presenter prepares GABA-A receptor. chronic administration of alcohol involved ily accessible, the Education Committee multiple choice questions that should be both alterations in the function and composi- believes that the focus should be on inter- presented on the screen throughout the talk, Ruth McKernan extended this theme by tion of GABA-A sub-units, and also, changes pretation of the data rather than simply in order to emphasize and highlight the showing how you could (with a huge amount in the production of endogenous modulators presenting it. main issues of the talk. The answers from of investment and effort) develop sub-types called the neurosteroids. the audience are instantaneously processed selective drugs, both agonists and inverse- The essence of the educational track is and presented on screen providing a direct agonists at the benzodiazapine receptor. She The session was extremely well received. focussed on interactive sessions in which feedback possibility. Doing so, participants also introduced the exciting new data that Certainly, in terms of quality and presenta- there is a continuous dialogue between the are able to be actively involved in the ses- extra synaptic GABA-A receptors (particularly tions it matched anything else at the meeting participants, moderators and presenters. sion, enabling them to compare their ideas those containing the delta sub-unit) may have and each presentation had a considerable with others, anonymously using the keypad a fundamentally different role in regulation of degree of questions and answers from quite a Keypad system system. brain function, and could be the site of action large number of top Americans in the field. As ECNP wants to differentiate the educa- for new drugs such as the sleep promoting tional track from the other sessions at the I hope that by introducing the keypad agent gaboxadol. Overall, I think it was a great success and I ECNP Congress, the Education Committee system, ECNP has found a different and know all the speakers were extremely grateful has decided to try to add a “key pad” system to more effective way to keep the uniqueness Anne Lingford-Hughes presented work on to have been invited to represent ECNP. all the educational sessions. This system ena- and the interactive component of the edu- imaging the GABA-A benzodiazapine receptor bles the presenters to ask the participants ques- cational track. in humans, showing the growing evidence that tions and to get a response in a few seconds. dysfunction of these receptors may contribute

Report by Katja Beesdo, Germany late life depression Alzheimer’s Disease”. Reports of the ECNP-ACNP These sessions were very stimulating and Based on my poster presentation at the 17th highly relevant to my own work. Exchange Winners 2004 ECNP congress in Stockholm I was chosen Last but not least, the poster sessions were to participate in the 43rd ACNP Annual a great experience. First of all, they got Meeting in Puerto Rico in December 2004 lots of attention from congress attendees he ECNP – ACNP Exchange Award has been established to promote exchange of the and to present the poster “Is generalized anx- – the basis for interesting discussions of the Tbest posters by young scientists at the ECNP and ACNP Congresses. For the winners iety disorder a chronic disorder? Predicting results. During my own presentation I had selected by ECNP, the award consists of a waived registration fee and reimbursement chronicity and spontaneous remission”. the chance to exchange opinions and experi- of travel and accommodation costs for the annual meeting of the American College ences with researchers in similar or different of Neuropsychopharmacology. Winners must present the (updated) selected poster or Mentor concept working fields. Visiting other presenting elaborated version at the ACNP meeting Winning the ECNP-ACNP exchange award researchers I got a wide overview of the tre- was a big surprise and a great honour for me, mendous work done in American psychiatric because only ACNP members and invited research. Report by Eduard Maron, Estonia gene promoter variants and psychiatric ill- guests are allowed to attend the ACNP con- ness. ference. The ACNP meeting was held in San Stimulating experience At the 17th ECNP Congress in Stockholm I Juan, Puerto Rico, in December 2004. In To sum up, the ACNP meeting was a great had the honour of receiving the 2004 ECNP- Unexpected encounters advance I was informed about the two men- and stimulating experience! I would like to ACNP Exchange Award, which supported According to the conditions of ACNP meet- tors who were assigned to me and about spe- thank the ECNP committee to have chosen participation in the 43rd ACNP Annual ings, participants had to meet at least three cial meetings established just for the travel my work for the ECNP-ACNP exchange Meeting in Puerto Rico in December 2004. new participants each day. It was not dif- awardees and their mentors (among them award. As each past travel awardee will ficult to do so if one takes into account the the travel awardee breakfast and luncheon) be invited to attend the next two ACNP The possibility to get to know the American lively interaction between participants. It to enable young scientists to get in contact conferences, I am already looking forward College of Neuropsychopharmacology was was impressive to discuss and talk with lead- with each other and to meet experienced to these. most exciting, as I had heard high opinions ing scientists, whose work help in ones own researchers. My mentors were Katherine expressed regarding the scientific quality research. In particular the meetings with Shears from Pittsburgh, Pennsylvania and of ACNP Meetings. My expectations of professors Jack Gorman, Andrew Goddard James Meador-Woodruff from Michigan. a very interesting programme came com- and David Goldman come to . Some Our first meeting was the travel awardee pletely true. of the meetings were also unexpected and breakfast at the start of the congress. Due Symposium ECNP at surprising. During my poster presentation I to the fact that we have very similar research ACNP 2004 Working days passed unnoticed met a doctor from Boston, who had worked interests, Katherine Shears and I kept meet- The meeting took place in the quaint part with scientists from my home university in ing up throughout the congress and finally Brain GABA-A receptors – 25 years of San Juan near the Old Town with beau- Tartu 25 years ago. The world is indeed a even discussed some projects we might carry of progress tiful views and a thrilling history. Warm small place. out together in the future. She introduced Chair: David J. Nutt, United weather and the excellent organisation con- me to many of her colleagues and even Kingdom tributed to an open and natural atmosphere Mentors enabled me to attend an interesting meeting during the conference. Nonetheless, the All together, the meeting was a very inter- that was not open to most congress partici- From binding site to molecular scientific programme was very meaningful esting and important experience for me. pants. All in all, I very much appreciated the function and embraced various actual and important Fortunately, being a past travel awardee mentor-concept because it allowed for new Uwe Rudolph, Switzerland fields in neuropsychopharmacology. I was I will be able to take part in two more contacts and possibilities regarding future really impressed by the high level of lectures ACNP meetings and I very much hope to projects. Subtypes as drug targets and presentations, some of which forced participate in these. I would also like to sin- Ruth McKernan, United Kingdom one to look at accepted things differently. It cerely thank my mentors, Professor Richard Scientific highlights seemed that working days, which continued Foltin and Elliot Stein, as well as Professor Turning to the congress itself, it was – as Imaging subtypes at times for more than 12 hours, passed for their personal support and expected – a very interesting and highly and receptor function unnoticed. recommendation during this meeting and scientific event. It was difficult to choose just Anne Lingford-Hughes, United to thank the ECNP Award Committee for one of the sessions scheduled at any given Kingdom One “minus” point of the conference was the award. time. However, there were some highlights the difficulty of making a choice between as the panel session on “Behavioral and neu- Modulation of GABA-a receptor sessions. In particular I was interested in rophysiological markers for risk and psycho- activity by brain steroidogenesis panel sessions devoted to such themes as pathology in adolescence” chaired by Daniel Giovanni Biggio, Italy New insights into panic disorder, ECNP Pine or the talk by Helena Kraemer “Are panel: brain GABA-A receptors – 25 years they one disorder or two? Methodological of progress and Novel considerations” within the panel session “Is

4 l aalbe tde i al agae areas language all in studies available all Systematically,involved. were countries EU all from advisors national as well as experts diagnostic with inquiries expert of series A Switzerland. and Norway membership as well as new – states the old as the well as – countries countries EU all included We youproceed? did how and chosen countries the were How of issue special a EuropeanNeuropsychopharmacology. in presented and be Amsterdam will in which of outcome the way,productive unprecedented an in linked been has expertise health-economic and cal epidemiologi EU Europe”.available in The brain the of disorders (EBC) of “Cost on initiative Council Brain European the with and fortunate to join our forces at the ECNP happy extremely therefore were We alone. might have much more impact than working tion that joining our forces across disciplines recogni increasing been has there that and problems similar from suffer neurosurgery psychology,clinical and neurologythat state to important is Thirdly,disorders. it mental on research applied and basic in funds more much next allocate should upcoming program the framework example for why on data and for reasons convincing for ask they and of priorities, and programs research future suggestions for call administration EU reasons. the and governments policy national example, For for needed urgently data were solid because timely, as regarded was force task the of installation the Secondly, issues. unresolved serious are there if done be to needs what and disagreement is why there artefacts, mythological simply are ies stud between prevalences which know to want They research. their for disorders tal men specific of incidence and bet prevalence need the about research epidemiologists from answers clinical ter and basic in Researchers EU. the in disorders mental of burden the and prevalence the concerning ECNP the in researchers among even oped devel has that confusion increasing the appropriately to respond to time simply was it First, issue: this on TaskForce a form to action ECNP the prompted reasons Several now? conducted study the is Why methodological differences! no almost are there differences for adjusting after fact in US the than way,the by population?” is, answer The that health mental better a have such Germans that it is “Why study, me, asking cross-national US-German a findings from study to of pre-publication response recent in a agency press German the from call a was example recentmore good A public. the and makers policy for also but researchers clinical and basic for 1 page fromH.-U. continued Wittchen for Youngin Scientists ECNP Worksahopthe at presentersNeuropsychopharmacology poster on the from selected havebeen results.youngscientists latest These their present will scientists 18 the At eerh teto, hr i ltl evidence little is there attention, research illegal in needing both depression,disorders and drug indications some for Except (2) studies. between differences methodological other and sampling design, account into taking after variation, or national cultural considerable for evidence is little there that remarkable it find I First, (1) findings? salient most the are What Neuropsychopharmacology in published ultimately findings, of interpretation the on also but methods, joint on only not agreed we meetings expert mental disorders were included. In a series of ing a total of over 150,000 subjects alone for lysed. A remarkable total of 27 studies cover data were accessed and systematically re-ana original the possible, if and, reviewed; were ones) cross-national and national (regional, th ECNP Congress two Hot Topics Sessions are scheduled at which 16 youngHot 16 two TopicsCongress which ECNP at scheduled areSessions interview Europe, March 2005. MarchEurope, 15.4. European ------coordinated and continuous high-quality high-quality programme. research continuous and coordinated a for point starting the be will project this established from the resulted that network interdisciplinary that hope I rather, again; no need to do the same type of ground work is there that hope I one. current the than ies stud better knowledgewith our expand and consolidate to studies EU-wide step coordinated need We modest direction. right a the into just forward clearly is study This repeated? be survey a such Should available. currently are data solid no were areas the in especially course, natural and factors risk about edge knowl our improve to studies and prospective epidemiology genetic and clinical funding for more I welcome highly perspective, also research would a from Certainly of size problem. the immense the of light the in are we underfunded how clear very made has EBC Olesen in his recent writings on behalf of the Jes politicians. our train from education and research, ing for funding better to data obtain such with succeed we that is wish ambitious more A forcefully. more patients our for lobby to able be jointly would and to de-stigmatise brain disorders in the public likely more be would we convergently, den bur and size on data and messages core the communicated alike researchers and doctors size and burden in a more convergent way. the If about communicate to start would we ful Task Force achievement, if, from now on, wonder a be would it that is wish modest A respond? cians politi should how – doctors should How disorders. mental of implications nomic treatmentfor careeco needs and health and disability,unmet and met utilization, service and impairment on data sufficient not are there disorders all personality across Finally, disorders. and disorders sleep disorders, control impulse like disorders, mental many for lacking also are data (b) miss; serious a prevalence in children and the elderly – both the estimate to available findings study cient suffi not are there (a) our namely knowledge; in deficits considerable also the study identified the importantly, more Maybe less costs. total the of for 5% than account overall, costs, treatment) (drug Pharmacological (disability). rectcosts indi of terms in occur costs of thirds two rates, treatment low of because Probably (7) incredible the year.per Euro 386,176,000 of exceed amount costs total the that conservatively estimated We high. dinarily extraor is system the for costs and disability of terms in burden the co-morbidity, high many disorders, delayed or no treatment and of persistence onset, of early prevalence, effects high combined the of result a As (6) disability.and disorder mental of terns pat co-morbid highly from suffer usually patients point that Atdisorders. the of onset after – decades even or – years many place takes usually treatment disorder, and psychotic mood the disabling with severely that of evidence exception also is There (5) countries. many in rarerelatively ally specialized fact treatment in the in mental health sector is actu care; primary to in likely occur most If is countries. intervention the EU treated, remain all patients almost all in untreated of majority The (4) 50%. exceed clearly to likely is brain the of disorder a experiencing for risk lifetime year.The each in disorder mental one least at from suffered population adult the of 1/3 (3) Thirdly,almost estimated, conservatively years. 20 past the overdisorders mental of prevalencethe in increase true a is there that ------before the congress! the before programmepersonalyour Plan ProgrammeCommittee Scientific Nutt,chair David revisited sessions Brainstorming Congress Party Congress For many years ECNP, in conjunction with ECNP,conjunction years in many For early the in scheduled be will Amsterdam in At discussion. sessions the participants, many of request the the specific initiate that interest of in field experts two session, each Within choice. their of topic a on ECNP members by sessions focussed small are sions ses Programme Brainstorming sessions. these of format Scientific successful the repeat the to decided Committee success this Stockholm) were very well received. Following The first brainstorming sessions (organised in painter, pewter makers or organ grinders. organ or painter,makers pewter Hindeloopen blower,a glass the shoemaker, old traditional Dutch crafts, like the wooden cheese throwing of of demonstration a watch and around,come tired are you When buttons! and cheese bears, traditional the won, be to prizes Dutch original some even are There mirrors. carnival the at fun have or gallery shooting the at rose a Win catching? cheese or contest cowmilking a at hand your try to yourself to a be a champion. Wouldn’t of you like heard prove and ever sleeves your up Rollshovelboard? instance, for you, Have food. traditional Dutch typical and entertainment days, old the from games with filled evening this miss to want Younot will Maxima. married Orange of Royal the Wedding instance in February 2002, when the Prince for occasions, special very on public the to open only is building historical This 1903. in Wilhelmina Queen by opened officially was It exchange. stock merchant’s a originally the Berlage, in van place Beurs take will party congress The to access provides changes, latest the gives access programme, updated full (continuously) the means to CIS congresses. the to prior weeks six internet the on System(CIS) Elsevier, has provided a Congress Information For details click on abstracts on click Fordetails hours 16.05 – 14.00 N-O Room 2005 23, OctoberSunday Hot TopicsInterface on Session hours 11.05 – 09.00 N-O Room 2005 23, OctoberSunday Hot TopicsPreclinicalNeuropsychopharmacologyon Session and programme at www.ecnp.at programme and Neuropsychopharmacology - 07.45 – 08.45 hours. A light breakfast will be 9 of will be scheduled on Sunday to Tuesday, total A from sessions. breakfast as morning Dutch evening! Dutch typical this during yourself enjoy and Come soup! bacon and peas meat), cooked well (very “draadjesvlees” only and one the or stew, carrot famous the hot(ch)-pot(ch), onions, with herring about How served. will be food Dutch traditional of selection A planner. personal a of means bycongress the through pos itinerary personal own your create to sibility the and text free or keyword author, on facility search a has papers, available all anti-depressants and dopamine, and OCD syndrome, metabolic on focus will heart- Tuesday’s sessions axis. and brain children/adolescents, in drugs psychotropic fluid, cerebrospinal are topics PTSD, and cognitive paradigms. On Monday research, CCK are Sunday Topicson served. nl

ecnp - 5 matters Award committee Sven Ove Ögren, Sweden Calendar of ECNP Events (chair) Francesc Artigas, Spain Michael Davidson, Israel Julien Mendlewicz, Belgium ECNP Congresses: Jean-Charles Schwartz October 22 - 26, 2005 18th ECNP Congress, Amsterdam, The Netherlands Hans-Ulrich Wittchen, September 16 - 20, 2006 19th ECNP Congress, Paris, France Germany October 13 - 17, 2007 20th ECNP Congress, Vienna, Austria August 30 – September 3, 2008 21st ECNP Congress, Barcelona, Spain Consensus September 12 - 16, 2009 22nd ECNP Congress, Istanbul, Turkey meeting committee Stuart A. Montgomery, United For further information: Organising secretariat: Scientific secretariat: Kingdom (chair) th Yves Lecrubier, France 18 ECNP Congress ECNP-Office Congrex Holland BV P.O. Box 85410 Jan M. van Ree, The P.O. Box 302 3508 AK Utrecht Netherlands 1000 AH Amsterdam The Netherlands Barbara J. van Zwieten-Boot, The Netherlands phone: +31 30 253 8567 the Netherlands phone: + 31 20 50 40 200 fax: +31 30 253 8568 fax: + 31 20 50 40 225 e-mail: [email protected] Educational committee e-mail: [email protected] website: www.ecnp.nl Joseph Zohar, Israel (chair) A. Carlo Altamura, Italy Celso Arango, Spain ECNP Workshop on Neuropsychopharma- Guy Goodwin, United cology for Young Scientists in Europe: Kingdom March 9 - 12, 2006 Cyril Höschl, Czech Republic Nice - France Yves Lecrubier Özden Palaoglu, Turkye Topics: Daniel Souery, Belgium • Molecular neuropsychopharmacology Hans-Ulrich Wittchen, • Behavioural pharmacology Germany • Clinical neuropsychopharmacology Events national societies • Anxiety: towards new drug targets Membership committee October 5 - 8, 2005 Hans-Jürgen Möller, Germany 24th symposium of the Arbeitsgemeinschaft für Neuropharmakologie und Pharmakopsychiatrie (chair) ECNP Consensus Meeting: (AGNP) Giovanni Biggio, Italy March 12 - 15, 2006 Munich - Germany Michel Bourin, France ECNP Consensus meeting, Nice - France for more information: www.agnp.de. Agneta Nordberg, Sweden Topic: Alexandra E. Sulcova, Czech Psychiatric disorders in older people November 4 – 5, 2005 Republic National Conference of Psychopharmacology Section of Polish Psychiatric Association Hans-Ulrich Wittchen, For further information: “Neuroanatomy and neuropsychology of psychiatric disorders: implications for treatment” Secretariat: Germany Bydgoszcz, Poland ECNP-Office P.O. Box 85410 Publication committee 3508 AK Utrecht Jan M. van Ree (chair) The Netherlands Julien Mendlewicz phone: +31 30 253 8567 Events related organizations Stuart A. Montgomery fax: +31 30 253 8568 November 2 - 5, 2005 David J. Nutt e-mail: [email protected] 5th Annual Meeting of the International College of Geriatric Psychoneuropharmacology Joseph Zohar Pittsburgh, Pennsylvania, USA for more information: www.icgp.org Workshop committee David J. Nutt (chair) August 24 – 28, 2006 Giovanni Biggio ecnp matters 16th Biennial Meeting of the International Society for Developmental Neuroscience Michel Hamon Banff, Alberta, Canada Tomas G.M. Hökfelt ecnp matters is a publication of the European Graphic Design for more information: www.isdn-conference.elsevier.com René S. Kahn College of Neuropsychopharmacology (ECNP). Pieter Hoogeveen Design and Art Direction Yves Lecrubier Edited by Web Design Julien Mendlewicz Maria C. Vrijmoed-de Vries, editor Elsa Edelenbos Sven Ove Ögren Jocelyn K. Koole-Krusemeijer, adviser Jan M. van Ree Jan M. van Ree, adviser Printing Information about national Editorial Committee Teewes Textpresse Grafische Bedrijven David J. Nutt (Chair) ECNP Award jury 2005 Illustrations: societies: Joseph Zohar The award committee: cartoons: Jan Milders Executive Committee The British Association for Psychopharmacology (BAP) held its summer meeting in Sven Ove Ögren, Sweden Call for copy Julien Mendlewicz (Belgium), President Harrogate in July, 2005. It is considered by many to be the hightlight of the BAP year. The (chair) Joseph Zohar (Israel), Vice-president Deadline next issue: 1 November 2005 Francesc Artigas, Spain David J. Nutt, (U.K.), President-elect annual guest lecture was presented by Jan M. van Ree, entitled “Opioids and the dynamics Copy (600 words maximum) can be sent to: Michael Davidson, Israel Yves Lecrubier (France), Past president of addiction”. ECNP-Office Hans-Ulrich Wittchen (Germany), Secretary The BAP launched the “Preclinical certificate in psychopharmacology” already in 2001. The Julien Mendlewicz, Belgium PO Box 85410 René S. Kahn (The Netherlands), Treasurer Jean-Charles Schwartz 3508 AK Utrecht aim of this important educational initiative is to increase awareness of, and interest in preclini- Celso Arango (Spain) Hans-Ulrich Wittchen, The Netherlands cal psychopharmacology through the provision of a series of training modules, which cover Giovanni Biggio (Italy) phone: +31 30 253 85 67 key aspects of research on animals and humans as well as career development in this field. Germany Guy M. Goodwin (U.K.) email: [email protected] and Michel Hamon (France) The BAP will continue its initiative on the Continuing Professional Development and Kjell Fuxe, Sweden, Tomas G.M. Hökfelt (Sweden) Copyright for all published material is held Certificate in Clinical Psychopharmacology programme. Winner ECNP Neuropsycho- Hans-Jürgen Möller (Germany) by ECNP unless specifically stated otherwise. pharmacology Award 2003 Agneta Nordberg (Sweden) ECNP matters is carefully prepared and published. During 2005 – 2006 BAP will publish consensus guideline statements covering: Treatment Özden Palaoglu (Turkey) The expressed views are not necessarily those of of anxiety disorders, ADHD in transition from child to adult and Clinical practice with anti- Nominating Committee ECNP or the editorial staff. They are the respon- dementia drugs. Contributors sibility of the named writer of the article. The 2007 Katja Beesdo editorial staff, however, does have the right to To be established. Mihai-Dumitru Gheorghe refuse or shorten copy. The writers are consulted The new board of the Psychopharmacology Section of the Polish Psychiatric Association Liedewij J. Jepsen about major changes in the copy. (PPA) consists of René S. Kahn Permission is given to reproduce the text of any President: Prof. Janusz K. Rybakowski Eduard Maron information found in this newsletter as long as the Vice-president: Prof. Malgorzata Rzewuska David J. Nutt sense is not distorted by omission or addition and Vice-president: Prof. Jan Horodnicki Sergey Seredenin the original place of publication is cited. Secretary: Dr. Justyna Pelka-Wysiecka Maria Gabriella Scordo Please inform the ECNP Office at [email protected] Treasurer: Dr. Jolanta Kucharska-Mazur Maria Vrijmoed-de Vries if you have news on the passing away of any ECNP Hans-Ulrich Wittchen members. Joseph Zohar Psychopharmacology Section of PPA is co-editor of the quarterly journal: Farmakoterapia w Psychiatrii i Neurologii (Pharmacotherapy in Psychiatry and Neurology). Prof. Malgorzata Rzewuska is the Editor-in-Chief of this journal.

6